Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, announced the successful initial use of its Artificial Intelligence (“AI”) program, named ADMAlytics. ADMAlytics combines AI and machine learning to improve and predict outcomes for production and operational processes. Recently, ADMA successfully produced its first batch of ASCENIV™ utilizing this innovative ADMAlytics software to prospectively automate and realize efficiency improvements to plasma pooling during commercial manufacturing. ADMA expects broad implementation of the new ADMAlytics capabilities has the potential to provide for rapid realization of efficiencies across the Company’s supply chain and production operations.

Recommended AI News: Samsung Electronics Collaborates With Arm on Optimized Next Gen Cortex-X CPU

“We’re proud to announce the successful development and implementation of our innovative ADMAlytics AI program,” said Adam Grossman, President and Chief Executive Officer of ADMA. “This achievement aligns seamlessly with our overarching mission to continuously innovate our production processes for specialty biologics, while also building on our reputation as a thought leader within the commercial specialty biologics markets for the patients our therapies serve.”

Related Posts
1 of 40,328

Recommended AI News: Ankura Launches Generative AI Tool, NoraGPT, Powered by OpenAI for Ankura Employees and Clients

Mr. Grossman continued, “The robust ADMAlytics AI program is designed to optimize and streamline our intricate production processes, delivering significant efficiencies throughout the organization. In the complex landscape of specialty biologics production, maintaining uninterrupted operations is paramount, and we believe that ADMAlytics will further bolster our commitment to ensuring continuity of patient care. We anticipate the program’s rollout across the entirety of the ADMA organization will, in due course, bring far reaching improvements and efficiencies across our operations and further support the Company’s earnings growth trajectory. We applaud our internal Information Technology team for their execution and success bringing this innovative software to commercial readiness and real-world application. ADMAlytics is another testament to our commitment to lead a new age of immunotechnology for specialty biologics.”

Recommended AI News: iQor Drives Digital Transformation in Retail With NICE CXone

[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]

Comments are closed.